Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis | |
Lyu WenWen1; Zhao QingChun2; Song DeHai1; Zhang JinJie1; Ding ZhaoXing1; Li BaoYuan1; Wei ChuanMei1 | |
刊名 | Chinese Medical Journal |
2016 | |
卷号 | 129期号:3页码:320-325 |
关键词 | Elderly Medicine R Meta-analysis Multiple Myeloma Thalidomide |
ISSN号 | 0366-6999 |
其他题名 | Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma:A Meta-analysis |
英文摘要 | Background: Thalidomide is an immunomodulatory and anti-angiogenic drug that has shown promise in patients with myeloma. Trials comparing efficacy of standard melphalan and prednisone (MP) therapy with MP plus thalidomide (MPT) in transplant-ineligible or elderly patients with multiple myeloma (MM) have provided conflicting evidence. This meta-analysis aimed to determine the efficacy and toxicity of thalidomide in previously untreated elderly patients with myeloma. Methods: Medline, the Cochrane Controlled Trials register, conference proceedings of the American Society of Hematology (1995–2014), the American Society of Clinical Oncology (1995–2014), and CBM, VIP, and CNKI databases were searched for randomized control trials with the use of the medical subject headings “MM “ and “thalidomide “. Trials were assessed by two reviewers for eligibility. Meta-analysis was conducted using a fixed effects model. Sensitivity analysis was performed to test the robustness of the findings. Results: Overall, seven trials were identified, covering a total of 1821 subjects. The summary hazard ratio (thalidomide vs. control) was 0.82 (95% confidence interval CI: 0.72–0.94) for overall survival (OS), and 0.65 (95% CI: 0.58–0.73) for progression-free survival, in favor of thalidomide treated group. The risk ratio of complete response with induction thalidomide was 3.48 (95% CI: 2.24–5.41). A higher rate of III/IV adverse events were observed in MPT arm compared with the MP arm. However, analysis of sub-groups administering anticoagulation as venous thromboembolism prophylaxis suggested no difference in relative risk of thrombotic events between two arms (RR = 1.47, 95% CI: 0.43–5.07, P = 0.54). Further analysis of trials on the treatment effects of MPT versus MP on adverse events-related mortality showed no statistical difference between two arms (RR = 1.24, 95% CI: 0.95–1.63 |
语种 | 英语 |
CSCD记录号 | CSCD:5625639 |
内容类型 | 期刊论文 |
源URL | [http://ir.imr.ac.cn/handle/321006/145213] |
专题 | 金属研究所_中国科学院金属研究所 |
作者单位 | 1.Binzhou Med University Hosp, Dept Pharm, Binzhou 256603, Shandong, Peoples R China 2.中国科学院金属研究所 |
推荐引用方式 GB/T 7714 | Lyu WenWen,Zhao QingChun,Song DeHai,et al. Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis[J]. Chinese Medical Journal,2016,129(3):320-325. |
APA | Lyu WenWen.,Zhao QingChun.,Song DeHai.,Zhang JinJie.,Ding ZhaoXing.,...&Wei ChuanMei.(2016).Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.Chinese Medical Journal,129(3),320-325. |
MLA | Lyu WenWen,et al."Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis".Chinese Medical Journal 129.3(2016):320-325. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论